CSBR Champions Oncology, Inc. - Common Stock
$5.07
Price · Aug 19, 2026
Fundamentals as of Jul 27, 2026
52W Range
$5–$8
6% of range
Analyst Rating
BUY
7 analysts
Price Target
—
P/E (TTM)
-63.4
ROE
-30.5%
Net Profit Margin
-2.0%
About Champions Oncology, Inc. - Common Stock Company overview from Wikipedia
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Read more
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
TumorGrafts
Champions TumorGrafts maintain the microenvironment surrounding the tumor and have been shown to have high correlation to the patient’s tumor. Due to this close resemblance to the human tumor, TumorGrafts are highly predictive of treatment outcomes in patients. Studies have shown the mouse avatars predict clinical benefit in 80% of patients. Approximately 450 TumorGrafts have been established as of April 2014.
TumorGrafts are also being used as a pre-clinical research tool to improve clinical drug development. Compared to traditional xenograft models, TumorGrafts, have a greater degree of accuracy in predicting clinical effectiveness of oncology drugs and thus can decrease clinical risk for drug developers. Champions has formed partnerships with multiple drug developers, including Teva and Pfizer.
The process
When a cancer patient undergoes surgery or biopsy, a living sample of the tumor is obtained and implanted into the mouse, creating a mouse avatar. Once the TumorGraft has successfully grown, the tumor is then propagated in a second generation of mice and tested against a panel of cancer drugs and drug combinations to help identify more accurately which treatment regimen is likely to be most effective in a specific patient. In this way, various drugs are tested on a live sample of the actual patient's tumor, rather than on the patient. This reduces the likelihood of treatment with ineffective drugs and their associated side effects, and it increases the likelihood of finding a treatment that will work against the patient's tumor. For patients whose tumors have also undergone molecular testing, such as next-generation sequencing, the selection of potential drugs is further guided by any and all applicable results. In the event the cancer progresses or recurs, Champions also banks, or stores, each successful TumorGraft for potential future patient use.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
CSBR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$5.07
Market Cap
$70M
P/E (TTM)
-63.4
EPS (TTM)
$-0.08
Revenue (TTM)
$59M
Div Yield
—
ROE
-30.5%
Debt/Equity
—
52W Range
$5 – $8
CSBR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
$59M
2018-04-30
→
2026-04-30
EPS
$-0.08
2018-04-30
→
2026-04-30
Free Cash Flow
$-5M
2017-04-30
→
2026-04-30
Margins
-2.0%
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
CSBR
Peer Median
P/E (TTM)
-63.4
31.9
P/S (TTM)
1.2
2.5
P/B
17.9
2.2
Price / FCF
-14.0
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
CSBR
Peer Median
Operating Margin
-1.9%
—
Net Profit Margin
-2.0%
-71.9%
ROA
-4.0%
-23.6%
ROE
-30.5%
-35.1%
ROIC
-36.6%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
CSBR
Peer Median
Current Ratio
1.0
4.5
Quick Ratio
0.9
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
CSBR
Peer Median
Revenue YoY
4.4%
—
Revenue CAGR 3Y
3.3%
—
Revenue CAGR 5Y
7.7%
—
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
CSBR
Peer Median
CSBR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
7 analysts
- Strong Buy 2 28.6%
- Buy 4 57.1%
- Hold 1 14.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.01%
Next Report
Sep 16, 2026
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.05 | $-0.05 | 0.00% |
| March 31, 2026 | $-0.02 | $0.09 | -0.11% |
| Dec. 31, 2025 | $0.02 | $0.01 | 0.01% |
| Sept. 30, 2025 | $0.02 | $-0.01 | 0.03% |
| June 30, 2025 | $-0.07 | $-0.20 | 0.13% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| CSBR | $83M | -74.5 | 4.4% | -2.0% | -30.5% | — |
| MXCT | $166M | -3.7 | -14.5% | -135.1% | -24.6% | 81.2% |
| QTRX | $297M | -2.5 | 1.1% | -77.1% | -36.4% | 46.8% |
| NAUT | $247M | -4.1 | — | — | -34.9% | — |
| SEER | — | -1.4 | 17.0% | — | — | — |
| RPID | — | -2.8 | 19.7% | -140.3% | -107.4% | — |
| HYFT | — | — | — | — | — | — |
| HBIO | $30M | -0.5 | -8.1% | -65.5% | -384.8% | 57.7% |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 15
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $3M | $20M | |
| Cost of Revenue | $31M | $28M | $29M | $30M | $24M | $21M | $17M | · | · | |
| R&D Expense | $9M | $7M | $10M | $12M | $9M | $7M | $6M | $5M | $4M | |
| SG&A Expense | $11M | $9M | $11M | $10M | $9M | $7M | $7M | $5M | $4M | |
| Operating Expenses | · | · | · | · | · | · | $34M | $27M | $22M | |
| Operating Income | $-1M | $5M | $-7M | $-5M | $607.0K | $366.0K | $-2M | $270.0K | $-1M | |
| Other Non-op | $211.0K | $73.0K | $48.0K | $-11.0K | $-24.0K | $71.0K | $-42.0K | $-39.0K | $-89.0K | |
| Pretax Income | $-929.0K | $5M | $-7M | $-5M | $583.0K | $437.0K | $-2M | $231.0K | $-1M | |
| Income Tax | $246.0K | $-75.0K | $-32.0K | $68.0K | $35.0K | $75.0K | $130.0K | $103.0K | $33.0K | |
| Net Income | $-1M | $5M | $-7M | $-5M | $548.0K | $362.0K | $-2M | $128.0K | $-1M | |
| EPS (Basic) | $-0.08 | $0.34 | $-0.54 | $-0.39 | $0.04 | $0.03 | $-0.18 | $0.01 | $-0.13 | |
| EPS (Diluted) | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 | $0.01 | $-0.13 | |
| Shares (Basic) | 13,832,385 | 13,659,786 | 13,547,604 | 13,541,559 | 13,197,170 | 13,138,995 | 11,843,463 | 11,340,184 | 10,991,105 | |
| Shares (Diluted) | 13,832,385 | 14,266,781 | 13,547,604 | 13,541,559 | 14,159,799 | 14,573,561 | 11,843,463 | 14,096,117 | 10,991,105 | |
| EBITDA | $260.0K | $6M | $-6M | $-3M | $2M | $2M | $-978.0K | $876.0K | $-994.0K |
Balance Sheet 22
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5M | $10M | $3M | $10M | $9M | $5M | $8M | $3M | $856.0K | |
| Receivables | $13M | $11M | $10M | $8M | $10M | $7M | $5M | $4M | $4M | |
| Prepaid Expense | $1M | $1M | $1M | $1M | $1M | $957.0K | $385.0K | $308.0K | $287.0K | |
| Current Assets | $19M | $22M | $14M | $19M | $20M | $13M | $13M | $8M | $5M | |
| PP&E (Net) | · | · | · | · | $7M | $6M | $4M | $3M | $2M | |
| PP&E (Gross) | $16M | $16M | $16M | $16M | $13M | $10M | $7M | $5M | $4M | |
| Accum. Depreciation | $13M | $12M | $10M | $9M | $6M | $4M | $3M | $2M | $1M | |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $670.0K | $669.0K | |
| Other Non-current Assets | $212.0K | $196.0K | $185.0K | $15.0K | $15.0K | $15.0K | $128.0K | $128.0K | $116.0K | |
| Total Assets | $27M | $32M | $26M | $34M | $35M | $28M | $21M | $11M | $8M | |
| Accounts Payable | $7M | $4M | $6M | $5M | $3M | $2M | $3M | $3M | $2M | |
| Accrued Liabilities | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $1M | $569.0K | |
| Current Liabilities | $20M | $24M | $22M | $22M | $17M | $11M | $12M | $8M | $7M | |
| Capital Leases | $3M | $5M | $6M | $7M | $8M | $9M | $3M | $0 | $17.0K | |
| Other Non-current Liabilities | $7.0K | $85.0K | $401.0K | $551.0K | $391.0K | $181.0K | $178.0K | $151.0K | $151.0K | |
| Total Liabilities | $23M | $29M | $28M | $30M | $26M | $20M | $16M | $9M | $8M | |
| Common Stock | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $13.0K | $13.0K | $12.0K | $11.0K | |
| Retained Earnings | $-81M | $-80M | $-85M | $-77M | $-72M | $-73M | $-73M | $-71M | $-71M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $74.0K | $0 | · | · | $0 | $1M | |
| Stockholders' Equity | $4M | $4M | $-2M | $5M | $9M | $7M | $5M | $2M | $3.0K | |
| Liabilities + Equity | $27M | $32M | $26M | $34M | $35M | $28M | $21M | $11M | $8M | |
| Shares Outstanding | 13,886,826 | 13,777,170 | 13,714,099 | 13,558,650 | 13,522,441 | 13,414,066 | 12,726,728 | 11,619,538 | 11,003,228 |
Cash Flow 14
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $2M | $2M | $2M | $2M | $925.0K | $825.0K | $606.0K | $360.0K | |
| Stock-based Comp | $1M | $654.0K | $1M | $864.0K | $912.0K | $598.0K | $600.0K | $636.0K | $1M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | |
| Other Non-cash | $-6M | $431.0K | $-2M | $6M | $4M | $-4M | $3M | $492.0K | $-1M | |
| Operating Cash Flow | $-4M | $7M | $-6M | $4M | $6M | $-2M | $3M | $2M | $-1M | |
| CapEx | $564.0K | $389.0K | $836.0K | $3M | $2M | $3M | $2M | $834.0K | $1M | |
| Investing Cash Flow | $-540.0K | $-389.0K | $-836.0K | $-3M | $-2M | $-3M | $-2M | $-834.0K | $-1M | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | · | $0 | $634.0K | $74.0K | $0 | · | · | · | · | |
| Net Stock Activity | · | $0 | $-634.0K | $-74.0K | · | · | · | · | $0 | |
| Financing Cash Flow | $99.0K | $170.0K | $-527.0K | $11.0K | $207.0K | $1M | $4M | $1M | $13.0K | |
| Net Change in Cash | $-5M | $7M | $-8M | $1M | $4M | $-4M | $5M | $2M | $-2M | |
| Taxes Paid | $242.0K | $43.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | $-5M | $7M | $-7M | $1M | $4M | $-5M | $685.0K | $1M | $-2M |
Profitability 7
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1.9% | 8.0% | -14.7% | -9.8% | 1.2% | 0.89% | · | 1.0% | · | |
| Net Margin | -2.0% | 8.3% | -14.5% | -9.9% | 1.1% | 0.88% | · | 0.47% | · | |
| Pretax Margin | -1.6% | 8.1% | -14.6% | -9.8% | 1.2% | 1.1% | · | 0.85% | · | |
| EBITDA Margin | 0.44% | 10.8% | -11.3% | -5.9% | 4.3% | 3.8% | · | 3.2% | · | |
| ROA | -4.0% | 16.1% | -24.1% | -15.3% | 1.7% | 1.5% | -12.5% | 1.3% | -18.6% | |
| ROE | -30.5% | 211.1% | 367.4% | -91.2% | 6.0% | 4.7% | -36.9% | 5.6% | -744.4% | |
| ROIC | -36.6% | 122.7% | 384.9% | -114.8% | 6.3% | 4.1% | -36.3% | 6.7% | -46165.5% |
Liquidity & Solvency 2
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.9 | 0.6 | 0.9 | 1.1 | 1.1 | 1.1 | 1.0 | 0.7 | |
| Quick Ratio | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 | 1.0 | 1.1 | 0.9 | 0.6 |
Efficiency 2
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 2.0 | 1.9 | 1.7 | 1.5 | 1.6 | 1.7 | · | 2.8 | · | |
| Receivables Turnover | 4.9 | 5.5 | 5.8 | 6.3 | 6.0 | 7.0 | · | 6.5 | · |
Growth Rates 7
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.4% | 13.5% | -6.9% | 9.7% | 19.7% | 27.8% | · | · | · | |
| Revenue CAGR 3Y | 3.3% | 5.1% | 6.9% | 18.8% | · | · | · | · | · | |
| Revenue CAGR 5Y | 7.7% | 12.1% | · | · | · | · | · | · | · | |
| EPS YoY | · | · | · | · | 100.0% | · | · | · | · | |
| EPS CAGR 3Y | · | 102.1% | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | · | · | 51.4% | · | · | · | · | |
| Net Income CAGR 3Y | · | 104.7% | · | · | · | · | · | · | · |
Valuation (TTM) 10
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $3M | $20M | |
| Net Income TTM | $-1M | $5M | $-7M | $-5M | $548.0K | $362.0K | $-2M | $128.0K | $-1M | |
| Market Cap | $83M | $99M | $66M | $67M | $104M | $144M | $98M | $106M | $48M | |
| P/E | -74.5 | 21.7 | -9.0 | -12.6 | 192.0 | 536.5 | -42.9 | 908.0 | -33.4 | |
| P/S | 1.4 | 1.7 | 1.3 | 1.2 | 2.1 | 3.5 | 3.1 | 36.4 | 2.4 | |
| P/B | 21.0 | 26.1 | -34.6 | 14.4 | 11.4 | 19.4 | 18.5 | 47.1 | 15918.0 | |
| P / Tangible Book | 23.0 | 28.7 | · | 15.5 | 11.9 | 20.3 | 20.6 | · | · | |
| P / Cash Flow | -18.5 | 13.3 | -10.7 | 16.8 | 16.0 | -85.6 | 33.8 | 56.7 | -39.0 | |
| P / FCF | -16.4 | 14.1 | -9.4 | 60.6 | 25.2 | -29.0 | 143.4 | 102.6 | -19.5 | |
| Earnings Yield | -1.3% | 4.6% | -11.1% | -7.9% | 0.52% | 0.19% | -2.3% | 0.11% | -3.0% |
Income Statement 14
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $17M | $15M | $14M | $12M | $17M | $13M | $14M | $14M | $12M | $12M | $13M | $13M | $13M | $14M | $14M | |
| Cost of Revenue | $7M | $9M | $7M | $8M | $7M | $7M | $7M | $7M | $7M | $8M | $7M | $8M | $7M | $8M | $7M | $7M | |
| R&D Expense | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | |
| SG&A Expense | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | |
| Operating Income | $-522.0K | $-276.0K | $185.0K | $-527.0K | $-2M | $4M | $732.0K | $1M | $-272.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $7.0K | $-284.0K | |
| Other Non-op | $27.0K | $39.0K | $70.0K | $75.0K | $42.0K | $19.0K | $7.0K | $5.0K | $81.0K | $58.0K | $-105.0K | $14.0K | $-20.0K | $36.0K | $-9.0K | $-18.0K | |
| Pretax Income | $-495.0K | $-237.0K | $255.0K | $-452.0K | $-2M | $5M | $739.0K | $1M | $-191.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $-2.0K | $-302.0K | |
| Income Tax | $172.0K | $42.0K | $18.0K | $14.0K | $-130.0K | $23.0K | $11.0K | $21.0K | $-82.0K | $11.0K | $11.0K | $28.0K | $20.0K | $17.0K | $14.0K | $17.0K | |
| Net Income | $-728.0K | $-279.0K | $268.0K | $-436.0K | $-2M | $4M | $728.0K | $1M | $-109.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $-16.0K | $-319.0K | |
| EPS (Basic) | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.14 | $0.33 | $0.05 | $0.10 | $-0.01 | $-0.19 | $-0.15 | $-0.19 | $-0.19 | $-0.18 | $0.00 | $-0.02 | |
| EPS (Diluted) | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.12 | $0.31 | $0.05 | $0.09 | $-0.01 | $-0.19 | $-0.15 | $-0.19 | $-0.19 | $-0.18 | $0.00 | $-0.02 | |
| Shares (Basic) | -27,634,739 | 13,886,797 | 13,791,913 | 13,788,414 | -27,228,373 | 13,700,627 | 13,593,766 | 13,593,766 | -27,049,997 | 13,593,758 | 13,497,061 | 13,506,782 | -27,068,159 | 13,558,642 | 13,528,643 | 13,522,433 | |
| Shares (Diluted) | -28,300,663 | 13,886,797 | 14,457,837 | 13,788,414 | -28,157,455 | 14,364,904 | 14,016,953 | 14,042,379 | -27,049,997 | 13,593,758 | 13,497,061 | 13,506,782 | -27,068,159 | 13,558,642 | 13,528,643 | 13,522,433 | |
| EBITDA | · | $65.0K | $542.0K | $-169.0K | · | $5M | $1M | $2M | · | $-2M | $-1M | $-2M | · | $-2M | $567.0K | $215.0K |
Balance Sheet 22
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5M | $7M | $9M | $10M | $10M | $3M | $3M | $3M | $3M | $4M | $6M | $5M | $10M | $12M | $11M | $8M | |
| Receivables | $13M | $12M | $12M | $9M | $11M | $16M | $10M | $9M | $10M | $8M | $8M | $9M | $8M | $8M | $9M | $9M | |
| Prepaid Expense | $1M | $991.0K | $1M | $1M | $1M | $713.0K | $860.0K | $1M | $1M | $835.0K | $780.0K | $1M | $1M | $661.0K | $834.0K | $958.0K | |
| Current Assets | $19M | $20M | $21M | $21M | $22M | $20M | $14M | $13M | $14M | $13M | $14M | $15M | $19M | $20M | $21M | $18M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $8M | $8M | |
| PP&E (Gross) | $16M | $16M | $16M | $16M | $16M | $17M | $16M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $14M | $14M | |
| Accum. Depreciation | $13M | $12M | $12M | $12M | $12M | $12M | $11M | $11M | $10M | $10M | $9M | $9M | $9M | $7M | $7M | $6M | |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | |
| Other Non-current Assets | $212.0K | $196.0K | $196.0K | $196.0K | $196.0K | $185.0K | $185.0K | $185.0K | $185.0K | $185.0K | $185.0K | $184.0K | $15.0K | $15.0K | $15.0K | $15.0K | |
| Total Assets | $27M | $28M | $30M | $31M | $32M | $31M | $25M | $25M | $26M | $27M | $28M | $30M | $34M | $36M | $36M | $34M | |
| Accounts Payable | $7M | $6M | $6M | $5M | $4M | $5M | $5M | $5M | $6M | $5M | $5M | $6M | $5M | $4M | $5M | $3M | |
| Accrued Liabilities | $3M | $3M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Current Liabilities | $20M | $21M | $22M | $23M | $24M | $20M | $19M | $19M | $22M | $22M | $21M | $20M | $22M | $21M | $19M | $17M | |
| Capital Leases | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $6M | $7M | $7M | $7M | $8M | $8M | $8M | |
| Other Non-current Liabilities | $7.0K | $27.0K | $46.0K | $66.0K | $85.0K | $285.0K | $324.0K | $363.0K | $401.0K | $439.0K | $476.0K | $514.0K | $551.0K | $588.0K | $624.0K | $660.0K | |
| Total Liabilities | $23M | $24M | $26M | $27M | $29M | $25M | $25M | $25M | $28M | $29M | $28M | $28M | $30M | $29M | $27M | $25M | |
| Common Stock | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Retained Earnings | $-81M | $-80M | $-80M | $-80M | $-80M | $-78M | $-83M | $-83M | $-85M | $-84M | $-82M | $-80M | $-77M | $-75M | $-72M | $-72M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $676.0K | $74.0K | · | · | · | |
| Stockholders' Equity | $4M | $4M | $4M | $4M | $4M | $5M | $681.0K | $-332.0K | $-2M | $-2M | $93.0K | $2M | $5M | $7M | $9M | $9M | |
| Liabilities + Equity | $27M | $28M | $30M | $31M | $32M | $31M | $25M | $25M | $26M | $27M | $28M | $30M | $34M | $36M | $36M | $34M | |
| Shares Outstanding | 13,886,826 | 13,886,826 | 13,886,326 | 13,788,421 | 13,777,170 | 13,705,570 | 13,698,903 | 13,593,766 | 13,593,766 | 13,593,766 | 13,593,766 | 13,484,110 | 13,544,228 | 13,558,650 | 13,558,650 | 13,522,441 |
Cash Flow 11
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $344.0K | $341.0K | $357.0K | $358.0K | $354.0K | $398.0K | $399.0K | $449.0K | $490.0K | $481.0K | $484.0K | $445.0K | $437.0K | $575.0K | $560.0K | $528.0K | |
| Stock-based Comp | $357.0K | $423.0K | $249.0K | $208.0K | $131.0K | $256.0K | $9.0K | $258.0K | $263.0K | $379.0K | $53.0K | $423.0K | $208.0K | $331.0K | $119.0K | $206.0K | |
| Other Non-cash | · | · | · | $470.0K | · | · | · | $-2M | · | · | · | $-2M | · | · | · | $-581.0K | |
| Operating Cash Flow | $-2M | $-1M | $-2M | $600.0K | $7M | $490.0K | $-283.0K | $311.0K | $-2M | $-919.0K | $589.0K | $-4M | $-692.0K | $2M | $3M | $-195.0K | |
| CapEx | $239.0K | $37.0K | $242.0K | $46.0K | $253.0K | $42.0K | $94.0K | $0 | $-3.0K | $18.0K | $79.0K | $668.0K | $760.0K | $754.0K | $604.0K | $754.0K | |
| Investing Cash Flow | $-238.0K | $-14.0K | $-242.0K | $-46.0K | $-253.0K | $-42.0K | $-94.0K | $0 | $3.0K | $-18.0K | $-79.0K | $-668.0K | $-760.0K | $-754.0K | $-604.0K | $-754.0K | |
| Stock Repurchased | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $32.0K | $602.0K | $74.0K | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | $0 | · | · | · | $-602.0K | · | · | · | · | |
| Financing Cash Flow | $-19.0K | $-36.0K | $168.0K | $-14.0K | $-32.0K | $0 | $239.0K | $-37.0K | $-37.0K | $-108.0K | $134.0K | $-590.0K | $-75.0K | $0 | $86.0K | $0 | |
| Net Change in Cash | $-2M | $-1M | $-2M | $540.0K | $7M | $448.0K | $-138.0K | $274.0K | $-2M | $-1M | $644.0K | $-5M | $-2M | $819.0K | $3M | $-949.0K | |
| Free Cash Flow | · | · | · | $554.0K | · | · | · | $311.0K | · | · | · | $-5M | · | · | · | $-949.0K |
Profitability 7
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -1.7% | 1.2% | -3.8% | · | 26.4% | 5.4% | 9.4% | · | -21.4% | -16.9% | -20.3% | · | -19.2% | 0.05% | -2.1% | |
| Net Margin | · | -1.7% | 1.8% | -3.1% | · | 26.4% | 5.4% | 9.3% | · | -21.1% | -17.9% | -20.4% | · | -19.1% | -0.11% | -2.3% | |
| Pretax Margin | · | -1.4% | 1.7% | -3.2% | · | 26.5% | 5.5% | 9.5% | · | -21.0% | -17.8% | -20.2% | · | -19.0% | -0.01% | -2.2% | |
| EBITDA Margin | · | 0.39% | 3.6% | -1.2% | · | 28.7% | 8.4% | 12.6% | · | -17.4% | -12.7% | -16.8% | · | -14.7% | 4.0% | 1.6% | |
| ROA | · | -0.94% | 0.97% | -1.6% | · | 15.7% | 2.7% | 4.8% | · | -8.0% | -6.4% | -8.0% | · | -7.0% | -0.05% | -1.0% | |
| ROE | · | -5.7% | 11.1% | -27.5% | · | 263.6% | 188.1% | 167.2% | · | -101.1% | -44.7% | -47.1% | · | -29.9% | -0.19% | -3.9% | |
| ROIC | · | -7.6% | 4.1% | -15.5% | · | 81.8% | 105.9% | -394.0% | · | 125.8% | -2113.4% | -135.6% | · | -35.0% | 0.61% | -3.3% |
Liquidity & Solvency 2
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 1.0 | 1.0 | 0.9 | · | 1.0 | 0.7 | 0.7 | · | 0.6 | 0.7 | 0.7 | · | 1.0 | 1.1 | 1.1 | |
| Quick Ratio | · | 0.9 | 0.9 | 0.9 | · | 1.0 | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.9 | 1.1 | 1.0 |
Efficiency 2
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.5 | 0.5 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | |
| Receivables Turnover | · | 1.2 | 1.4 | 1.5 | · | 1.4 | 1.5 | 1.6 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.7 | 1.6 |
Valuation (TTM) 10
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $63M | $60M | $59M | · | $57M | $51M | $50M | · | $49M | $51M | $53M | · | $54M | $53M | $50M | |
| Net Income TTM | · | $4M | $5M | $6M | · | $4M | $-3M | $-6M | · | $-10M | $-7M | $-5M | · | $-2M | $729.0K | $573.0K | |
| Market Cap | · | $102M | $95M | $87M | · | $151M | $54M | $65M | · | $79M | $74M | $88M | · | $56M | $94M | $117M | |
| P/E | · | 26.1 | 19.5 | 15.0 | · | 42.3 | -19.6 | -10.9 | · | -8.2 | -10.5 | -16.7 | · | -27.4 | 138.8 | 216.5 | |
| P/S | · | 1.6 | 1.6 | 1.5 | · | 2.7 | 1.0 | 1.3 | · | 1.6 | 1.4 | 1.6 | · | 1.0 | 1.8 | 2.3 | |
| P/B | · | 23.7 | 22.7 | 24.8 | · | 27.5 | 78.7 | -196.1 | · | -38.4 | 798.1 | 46.1 | · | 7.9 | 10.3 | 13.0 | |
| P / Tangible Book | · | 25.7 | 24.7 | 27.5 | · | 29.3 | 154.8 | · | · | · | · | 55.9 | · | 8.3 | 10.6 | 13.5 | |
| P / Cash Flow | · | · | · | 145.2 | · | · | · | 209.4 | · | · | · | -22.0 | · | · | · | -600.5 | |
| P / FCF | · | · | · | 157.3 | · | · | · | 209.4 | · | · | · | -18.8 | · | · | · | -123.4 | |
| Earnings Yield | · | 3.8% | 5.1% | 6.7% | · | 2.4% | -5.1% | -9.2% | · | -12.2% | -9.5% | -6.0% | · | -3.6% | 0.72% | 0.46% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | |
|---|---|---|---|---|---|
| Revenue | $59M | $57M | $50M | $54M | $49M |
| Operating Margin % | -1.9% | 8.0% | -14.7% | -9.8% | 1.2% |
| Net Income | $-1M | $5M | $-7M | $-5M | $548.0K |
| Diluted EPS | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 |
Balance Sheet
| 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | |
|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.9 | 0.6 | 0.9 | 1.1 |
| Quick Ratio | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 |
Cash Flow
| 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | |
|---|---|---|---|---|---|
| Free Cash Flow | $-5M | $7M | $-7M | $1M | $4M |
Trading Signals Recent buy/sell signals with entry price and risk/reward ratio
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 29 filers · $34.2M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 7 (+3 vs prior Q) | 2 (-3 vs prior Q) | 2 (-3 vs prior Q) | 7 (+1 vs prior Q) | -27K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BATTERY MANAGEMENT CORP. | $14,917,506 | 2,421,673 | 43.56% | Shares |
| NEA Management Company, LLC | $10,556,515 | 1,713,720 | 30.82% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,856,334 | 301,353 | 5.42% | Shares |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $1,821,253 | 295,658 | 5.32% | Shares |
| MORGAN STANLEY | $1,450,064 | 235,400 | 4.23% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $856,480 | 139,039 | 2.50% | Shares |
| Mink Brook Asset Management LLC | $685,842 | 111,338 | 2.00% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $392,213 | 63,653 | 1.15% | Shares |
| HighTower Advisors, LLC | $258,110 | 41,901 | 0.75% | Shares |
| VANGUARD GROUP INC | $227,975 | 32,992 | 0.67% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $204,752 | 33,239 | 0.60% | Shares |
| NORTHERN TRUST CORP | $171,926 | 27,910 | 0.50% | Shares |
| STATE STREET CORP | $161,410 | 26,203 | 0.47% | Shares |
| BANK OF AMERICA CORP /DE/ | $134,152 | 21,778 | 0.39% | Shares |
| Bank of New York Mellon Corp | $130,068 | 21,115 | 0.38% | Shares |
| CITADEL ADVISORS LLC | $112,697 | 18,295 | 0.33% | Shares |
| ESSEX INVESTMENT MANAGEMENT CO LLC | $112,241 | 18,221 | 0.33% | Shares |
| Mesirow Financial Investment Management, Inc. | $97,328 | 15,800 | 0.28% | Shares |
| MERCER GLOBAL ADVISORS INC /ADV | $78,694 | 12,775 | 0.23% | Shares |
| Vanguard Global Advisers, LLC | $12,893 | 2,093 | 0.04% | Shares |
| BlackRock, Inc. | $8,624 | 1,400 | 0.03% | Shares |
| ACADIAN ASSET MANAGEMENT LLC | $125 | 20,523 | 0.00% | Shares |
| BARCLAYS PLC | $80 | 13 | 0.00% | Shares |
| Cambridge Investment Research Advisors, Inc. | $75 | 12,252 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $71 | 11 | 0.00% | Shares |
| Cassaday & Co Wealth Management LLC | $62 | 10 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $25 | 4 | 0.00% | Shares |
| FMR LLC | $5 | 1 | 0.00% | Shares |
| Capital Advisors, Ltd. LLC | $0 | 48 | 0.00% | Shares |
Company insiders 14 insiders · 5 officers · 9 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Joel Ackerman | Chief Executive Officer | Nov. 19, 2015 A | 3,643,000 | 0 | 0 | $0 |
| CHAMPIONS SPORTS INC | Chairman, President and CEO | Oct. 11, 2004 P | 9,548,000 | 0 | 0 | $0 |
| Ronnie Morris | President | Nov. 19, 2015 A | 3,643,000 | 0 | 0 | $0 |
| Douglas D Burkett | President | Oct. 3, 2008 P | — | 0 | 0 | $0 |
| David Barry Miller | Vice President, Finance | March 16, 2015 A | — | 0 | 0 | $0 |
| Scott R. Tobin | Director | Oct. 12, 2021 M | 20,000 | 0 | 0 | $0 |
| Daniel Newman Mendelson | Director | Nov. 1, 2016 A | 750,000 | 0 | 0 | $0 |
| David Sidransky | Director | Nov. 1, 2016 A | 10,675,000 | 0 | 0 | $0 |
| Abba David Poliakoff | Director | Nov. 2, 2015 A | 638,667 | 0 | 0 | $0 |
| Arthur G Epker III | Director | Oct. 13, 2014 A | — | 0 | 0 | $0 |
| Ana Stancic | Director | July 14, 2011 A | — | 0 | 0 | $0 |
| Michael M. Brown | 10% owner | Jan. 28, 2013 A | 16,031,040 | 0 | 0 | $0 |
| James Martell | — | Jan. 6, 2012 G | 1,784,828 | 0 | 0 | $0 |
| Durwood Settles | — | Jan. 15, 2007 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 9 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| New Enterprise Associates 14, L.P., NEA Partners 14, L.P., NEA 14 GP, LTD, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Mohamad Makhzoumi, Scott D. Sandell ×2 filings | May 6, 2024 | — | Initial filing | — | SEC |
| Norman H. Pessin, Brian Pessin ×2 filings | Aug. 8, 2017 | — | Initial filing | Passive investment | SEC |
| PAR Investment Partners, L.P., PAR Group, L.P., PAR Capital Management, Inc., Arthur G. Epker, III ×4 filings | Oct. 28, 2016 | — | Initial filing | — | SEC |
| Joel Ackerman ×2 filings | March 23, 2015 | — | Initial filing | Passive investment | SEC |
| Ronnie Morris ×2 filings | March 23, 2015 | — | Initial filing | Passive investment | SEC |
| Battery Ventures IX, L.P., Battery Investment Partners IX, LLC, Battery Partners IX, LLC, Battery Management Corp., Scott R. Tobin, Thomas J. Crotty, Richard D. Frisbie, Kenneth P Lawler, R. David Tabors, Roger H. Lee, Neeraj Agrawal, Michael M. Brown, Jesse Feldman ×4 filings | March 16, 2015 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | May 29, 2007 | — | Initial filing | — | SEC |
| Manuel Hidalgo. | Jan. 18, 2007 | — | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Jan. 11, 2007 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 5 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| DCOR · Dimensional ETF Trust | 0.00% | 808 NS | April 30, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.00% | 201 NS | April 30, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | July 15, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | — | — | July 15, 2026 | Daily |
| IWC · iShares Trust | — | — | Aug. 18, 2026 | Daily |